[Event Report] Roundtable – Preparatory Meeting: The Management Structure and FY2019 Activities of AMR Alliance Japan (May 19, 2019)
date : 4/12/2019
Every year, Antimicrobial Resistance (AMR) kills approximately 700,000 people globally. In Japan, AMR has become a major challenge for many medical facilities, with cases of community-acquired drug-resistant infections on the rise nationally. To combat this issue, Japan enacted a National Action Plan on Antimicrobial Resistance in April 2016.
Sensing the growing concern about AMR domestically and abroad, HGPI has taken the initiative to host multiple expert meetings on this subject since 2016. Over the course of those expert meetings, it was suggested that the establishment of an independent platform for multi-stakeholder discussion on AMR was needed to encourage more impactful collaborations on the AMR policies.
To that end, in September 2018, HGPI joined together with eight Japanese medical societies involved with infectious disease medicine to establish AMR Alliance Japan, a multi-stakeholder, collaborative body that will work to improve public health by promoting AMR countermeasures.
During this preparatory meeting, representatives of participating academic societies and FY2018 project sponsors came together to discuss the management structure of AMR Alliance Japan and the actions to be carried out by the Alliance in FY2019.
Participants: AMR Alliance Japan academic society members and corporate stakeholders
Opening (explanatory introduction)
Matt McEnany (Manager, Health and Global Policy Institute)
Roundtable Speakers (alphabetical order by last name)
Yusuke Ariyoshi (Director, Healthcare Policy, Government Affairs Dept., Shionogi & Co., Ltd.)
Hiroshi Kiyota (President, Japanese Society of Chemotherapy / Professor, Department of Urology, The Jikei University Katsushika Medical Center)
Shinya Nagase (Director, Diagnostic Systems, BD Life Sciences, Nippon Becton Dickinson Company, Ltd.)
Ryoji Noritake (CEO, Board Member, Health and Global Policy Institute)
Masahiro Okuda (President, Japanese Society of Pharmaceutical Health Care and Sciences / Professor, Faculty of Medicine, Mie University Graduate School)
Akio Ozaki (Director, Public and Industry Policy, Health Policy, MSD K. K.)
Kazutoshi Shibuya (President, The Japanese Society for Medical Mycology / Professor, Department of Surgical Pathology, Toho University)
Yoshinobu Takakura (Vice President, Candidate for President, The Pharmaceutical Society of Japan, / Professor, Graduate School of Pharmaceutical Sciences, Kyoto University)
Kazuhiro Tateda (President, The Japanese Association for Infectious Diseases / President, The Japanese Society for Clinical Microbiology / Professor, Department of Microbiology and Infectious Diseases, Toho University)
Yasunori Tawaragi (Director, International Affairs, Japan Pharmaceutical Manufacturers Association)
Masaki Yoshida (President, Japanese Society for Infection Prevention and Control / Professor, Department of Infectious Disease and Infection Control, The Jikei University School of Medicine)